Eli Lilly Announces Positive News for Shareholders Amid Weight Loss Drug Market Growth
Eli Lilly's weight loss drugs, particularly tirzepatide (Mounjaro and Zepbound), have driven significant revenue growth. Despite competition from Novo Nordisk and potential future entrants like Pfizer, Eli Lilly recently secured approval for an oral version of its drug during a recent earnings call.
Topics: Eli Lilly GLP-1 class of drugs Mounjaro weight loss drugs Zepbound